SAN FRANCISCO - Blend Labs Inc. (NYSE: BLND), a provider of digital ... deepens relationships from the very first interaction." The solution is designed to cater to various business structures ...

Oral submucous fibrosis (OSF) is a chronic condition commonly affecting the oral mucosa, causing an excessive buildup of collagen that disrupts tissue function and increases the risk of cancer.

Inertial Labs, a VIAVI Solutions Inc. Company ... the M-AJ-QUATRO is engineered to withstand extreme conditions, making it an ideal solution for defense and aerospace applications.

concentrated oral solution approved for the treatment of infantile spasms in pediatric patients one month to two years old for whom the potential benefits outweigh the potential risk of vision loss.

PITTSBURGH, March 24, 2025 /PRNewswire/ -- PANTHERx ® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected ...

VERO BEACH, Fla., March 1, 2025 /PRNewswire/ -- QOL Medical, LLC, a ground-breaking rare disease pharmaceutical company, has announced Sucraid ® (sacrosidase) Oral Solution has been shown to be ...

Liporaxel oral solution showed non-inferiority in PFS and superiority in OS compared to IV Liporaxel in advanced gastric cancer patients. The phase 3 trial involved 536 patients, with a median OS of 9 ...

Phase II preoperative pembrolizumab for MSI high or MSS/PD-L1 gastric cancer followed by surgery and adjuvant therapy with pembrolizumab (NCT03257163): Results of a multicenter study. This is an ASCO ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of lacosamide oral solution, 10 mg/mL. Glenmark’s lacosamide oral solution, 10 mg/mL is bioequivalent and therapeutically equivalent ...

The FDA approval marks the first oral solution indicated for patients with different forms of leukemia. “We are thrilled to offer an oral solution option for patients with leukemia and other ...